Omega-3 Fatty Acids

DHA: Structural Role in Neuronal Membranes

DHA is uniquely suited to neuronal membrane function by its physical properties. Its 22-carbon chain with six double bonds creates an extremely flexible, low-rigidity fatty acid that inserts into membrane phospholipids (particularly phosphatidylserine and phosphatidylethanolamine) and dramatically increases membrane fluidity and molecular dynamics. This fluidity is essential for:

• Receptor conformational changes: GPCR signaling (serotonin, dopamine, acetylcholine receptors) requires rapid conformational dynamics that are impaired in rigid, DHA-depleted membranes
• Ion channel kinetics: Voltage-gated sodium, potassium, and calcium channels have altered kinetics in DHA-deficient membranes
• Synapse formation and plasticity: DHA promotes dendritic spine morphology changes underlying LTP; DHA-derived protectins (neuroprotectin D1, NPD1) promote neuronal survival and synaptic plasticity
• Protein-lipid interactions: Signaling proteins that insert into or associate with the membrane (PKC, G-proteins, BDNF receptor TrkB) require specific membrane compositions for optimal function

DHA is highly concentrated in the sn-2 position of phosphatidylserine, the phospholipid at the inner leaflet of neuronal membranes (discussed under phosphatidylserine). The brain preferentially retains DHA even during dietary deficiency, prioritizing it above other tissues — but chronic deficiency does produce measurable reductions in brain DHA content with functional consequences.

EPA: Anti-inflammatory and Mood Effects

EPA is the precursor to the 3-series prostaglandins and leukotrienes — less pro-inflammatory than the 2-series (derived from arachidonic acid, AA). More significantly, EPA (along with DHA) is the precursor to specialized pro-resolving mediators (SPMs): resolvins (E-series from EPA, D-series from DHA), protectins (from DHA), and maresins. SPMs actively resolve inflammation — they counteract pro-inflammatory cytokines, promote macrophage clearance of cellular debris, and restore tissue homeostasis. This active resolution of inflammation, rather than simple anti-inflammatory suppression, represents a novel mechanism distinct from NSAIDs.

In the context of mood and depression, the evidence for EPA is notably stronger than for DHA:

• Antidepressant trials: Meta-analyses show that omega-3 preparations with EPA:DHA ratio >2:1 are more effective for depression than DHA-predominant preparations
• Mechanisms proposed: EPA may reduce neuroinflammation (elevated pro-inflammatory cytokines are found in a subset of depressed patients), modulate serotonin and dopamine neurotransmission, and reduce HPA axis reactivity
• Augmentation: High-EPA omega-3s at 1–4 g/day enhance response to SSRI antidepressants in several trials

Docosanoids and Neuroprotection

DHA-derived metabolites — particularly neuroprotectin D1 (NPD1) — are potent neuroprotective agents. NPD1 induces anti-apoptotic gene expression (upregulates Bcl-2, Bcl-XL; downregulates Bax, Bad), reduces neuroinflammation, and promotes survival of neurons under oxidative stress. This neuroprotective metabolome downstream of DHA represents an important mechanism for omega-3's documented protective effects in aging and neurological disease.

Pharmacokinetics

Marine omega-3s (from fish oil, krill oil, algal oil) are absorbed in the small intestine with dietary fat. Triglyceride-form fish oil has comparable absorption to ethyl ester form when taken with a fatty meal; krill oil's phospholipid-bound omega-3s may have slightly better bioavailability. EPA and DHA are incorporated into plasma phospholipids within hours and into tissue phospholipids over days to weeks. Brain DHA levels increase with sustained supplementation but slowly — reflecting turnover rates in structural membrane phospholipids. Half-time for brain DHA enrichment in animal studies is measured in weeks.

Essential Fatty Acids: Early Discovery

The essentiality of polyunsaturated fatty acids was established by George Burr and Mildred Burr at the University of Minnesota in 1929–1930. Feeding rats a fat-free diet produced a distinctive deficiency syndrome — scaly skin, impaired reproduction, and growth failure — that was corrected by dietary fat. The specific omega-3 and omega-6 families were characterized over subsequent decades through the work of Holman and others at the Hormel Institute, who established the chemical structures and metabolic relationships of the major PUFAs.

DHA and the Brain: The Dyerberg and Bang Connection

Systematic interest in the cardiovascular and neurological benefits of marine omega-3s was triggered by epidemiological observations in Greenlandic Inuit populations by Danish physicians Jørn Dyerberg and Hans Olaf Bang in the early 1970s. Despite a diet extremely high in animal fat, Greenlandic Inuit had remarkably low rates of cardiovascular disease. Dyerberg and Bang identified high EPA and DHA intake as the distinctive feature of the Inuit diet and proposed this explained the cardiovascular protection. Their 1978 Lancet paper on "Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis" launched the omega-3 field.

DHA and Brain Development

The role of DHA in brain development became an intense focus of research in the 1980s–1990s, driven in part by comparisons of breast-fed infants (who receive DHA through breast milk) with formula-fed infants (early formulas lacked DHA) on neurodevelopmental outcomes. This research, led by groups including Michael Crawford at the Institute of Brain Chemistry and Human Nutrition (London) and Ricardo Uauy, showed that DHA accretion in the fetal brain in the third trimester and early infancy is essential for optimal neurodevelopment, visual function, and cognitive performance. DHA was added to infant formula globally beginning in the late 1990s and early 2000s following this work.

Omega-3s and Psychiatry

Interest in omega-3s in psychiatry was stimulated by Andrew Stoll at Harvard in the late 1990s, who conducted a small but striking randomized trial showing omega-3 supplementation was dramatically superior to placebo in preventing manic episodes in bipolar disorder. Subsequent research produced a complex but generally supportive picture: EPA-predominant omega-3s have antidepressant efficacy in unipolar depression, particularly as augmentation; DHA-predominant formulas perform less well. Purified EPA (Vascepa, 4 g/day) was approved for cardiovascular risk reduction in 2019 based on the REDUCE-IT trial, which showed significant reductions in major adverse cardiovascular events in high-risk patients receiving high-dose EPA.